论文部分内容阅读
目的 :观察国产表柔比星为主的联合化疗方案治疗非霍奇金淋巴瘤、乳腺癌、非小细胞肺癌的疗效和不良反应。方法 :多个中心应用统一的以国产表柔比星为主的联合化疗方案 ,对治疗 6 7例患者的疗效和不良反应进行分析。结果 :非霍奇金淋巴瘤 2 6例中 ,完全缓解 3例 ,部分缓解 15例 ,有效率 6 9.2 %。乳腺癌 2 3例中 ,完全缓解 1例 ,部分缓解 11例 ,有效率 5 2 .2 %。非小细胞肺癌 18例中 ,完全缓解 1例 ,部分缓解 5例 ,有效率 33.3%。全组总有效率为 5 3.7%。不良反应以骨髓抑制和脱发发生率最高 ,Ⅲ度脱发 11.9% ,Ⅲ度白细胞下降 2 0 .9% ,Ⅲ /Ⅳ度血小板下降 7.5 % ,Ⅰ度心脏毒性仅见 1例 ,本品耐受性良好。结论 :国产与进口表柔比星的疗效和不良反应相近 ,值得临床推广使用
Objective: To observe the efficacy and adverse reactions of domestic epirubicin-based combination chemotherapy in the treatment of non-Hodgkin’s lymphoma, breast cancer, and non-small cell lung cancer. Methods: Multiple centers used a unified combined chemotherapy regimen based on domestic epirubicin to analyze the efficacy and adverse reactions of 67 patients. Results: Of the 26 cases of non-Hodgkin’s lymphoma, 3 cases were complete remission, 15 cases were partial remission, and the effective rate was 69.2%. Of the 23 patients with breast cancer, 1 had complete remission, 11 had partial remission, and an effective rate of 52. 2%. Among 18 cases of non-small cell lung cancer, 1 case was complete remission, 5 cases were partial remission, and the effective rate was 33.3%. The total effective rate in the whole group was 5 3.7%. The incidence of myelosuppression and alopecia was highest in adverse reactions, 11.9% in III degree, 20.9% in III degree leukocytes, 7.5% in III/IV platelets, and only 1 case in degree I cardiac toxicity. This product was well tolerated. . Conclusion: The efficacy and adverse reactions of domestic and imported epirubicin are similar and worthy of clinical application